A Cost-Effectiveness Analysis of Three PARP Inhibitors for Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

Parp Inhibitors ◽

Platinum Sensitive ◽

A cost-effectiveness analysis of three PARP inhibitors for maintenance therapy in platinum-sensitive recurrent ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.04.027 ◽

2018 ◽

Vol 149 ◽

pp. 9 ◽

Cited By ~ 1

Author(s):

A.Y. Liu ◽

J.G. Cohen ◽

C. Walsh ◽

C.H. Holschneider ◽

A.K. Sinno

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Parp Inhibitors ◽

Platinum Sensitive ◽

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.08.013 ◽

2015 ◽

Vol 139 (1) ◽

pp. 59-62 ◽

Cited By ~ 25

Author(s):

Haller J. Smith ◽

Christen L. Walters Haygood ◽

Rebecca C. Arend ◽

Charles A. Leath ◽

J. Michael Straughn

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Platinum Sensitive ◽

Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.08.003 ◽

2020 ◽

Vol 159 (2) ◽

pp. 483-490 ◽

Cited By ~ 1

Author(s):

Rafael Gonzalez ◽

Laura J. Havrilesky ◽

Evan R. Myers ◽

Angeles Alvarez Secord ◽

Joseph A. Dottino ◽

...

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Parp Inhibitors ◽

Advanced Stage ◽

Newly Diagnosed ◽

Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1954506 ◽

2021 ◽

Author(s):

John Hang Leung ◽

Hui-Chu Lang ◽

Shyh-Yau Wang ◽

Hsueh Fang Lo ◽

Agnes LF Chan

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Platinum Sensitive ◽

Management of platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

Gynecologic Oncology ◽

10.1016/j.ygyno.2007.06.029 ◽

2007 ◽

Vol 107 (2) ◽

pp. 211-218 ◽

Cited By ~ 18

Author(s):

L HAVRILESKY ◽

A SECORD ◽

S KULASINGAM ◽

E MYERS

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Platinum Sensitive ◽

Adding bevacizumab to single-agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost-effectiveness analysis of the AURELIA trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.04.116 ◽

2016 ◽

Vol 141 ◽

pp. 36

Author(s):

W.Z. Wysham ◽

E.M. Schaffer ◽

T.M. Coles ◽

D.R. Roque ◽

S.B. Wheeler ◽

...

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Single Agent ◽

Effectiveness Analysis ◽

Platinum Resistant ◽

Single Agent Chemotherapy

EP795 Searching for the best maintenance therapy in platinum-sensitive recurrent ovarian cancer: bevacizumab or PARP-inhibitors? A network meta-analysis

10.1136/ijgc-2019-esgo.846 ◽

2019 ◽

Author(s):

M Bartoletti ◽

G Pelizzari ◽

L Bortot ◽

M Giavarra ◽

MG Vitale ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Meta Analysis ◽

Parp Inhibitors ◽

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum Sensitive< Recurrent Ovarian Cancer

Value in Health ◽

10.1016/j.jval.2018.04.185 ◽

2018 ◽

Vol 21 ◽

pp. S29

Author(s):

L Zhong ◽

AT Tran ◽

T Tomasino ◽

JA Smith ◽

EK Nugent

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

PARP inhibitors as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: Can we afford it?

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.017 ◽

2015 ◽

Vol 137 ◽

pp. 9 ◽

Cited By ~ 1

Author(s):

H.J. Smith ◽

C.L. Walters Haygood ◽

R.C. Arend ◽

C.A. Leath ◽

J.M. Straughn

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Parp Inhibitors ◽

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2018.24.12.1219 ◽

2018 ◽

Vol 24 (12) ◽

pp. 1219-1228 ◽

Cited By ~ 2

Author(s):

Lixian Zhong ◽

Anh Thu Tran ◽

Taylor Tomasino ◽

Elizabeth Nugent ◽

Judith A. Smith

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽